Bylvay

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Odevixibat

Available from:

Albireo

ATC code:

A05AX

INN (International Name):

odevixibat

Therapeutic group:

Bile i jetrena terapija

Therapeutic area:

Cholestasis, Intrahepatic

Therapeutic indications:

Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older (see sections 4. 4 i 5.

Product summary:

Revision: 3

Authorization status:

odobren

Authorization date:

2021-07-16

Patient Information leaflet

                                37
B.
UPUTA O LIJEKU
38
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA
BYLVAY 200 MIKROGRAMA TVRDE KAPSULE
BYLVAY 400 MIKROGRAMA TVRDE KAPSULE
BYLVAY 600 MIKROGRAMA TVRDE KAPSULE
BYLVAY 1200 MIKROGRAMA TVRDE KAPSULE
odeviksibat
O
vaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Prijavom svih sumnji na nuspojavu i Vi možete pomoći
(za postupak prijavljivanja
nuspojava pogledajte dio 4.).
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
•
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
•
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
•
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
•
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To
uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi
(vidjeti dio 4.).
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Bylvay i za što se koristi
2.
Što morate znati prije nego počnete uzimati Bylvay
3.
Kako uzimati Bylvay
4.
Moguće nuspojave
5.
Kako čuvati Bylvay
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE BYLVAY I ZA ŠTO SE KORISTI
Bylvay sadrži djelatnu tvar odeviksibat. Odeviksibat je lijek koji
pospješuje uklanjanje iz tijela tvari
koje se nazivaju žučnim kiselinama. Žučne kiseline su sastavnice
probavne tekućine koja se naziva
žuč, a koju stvara jetra i koja se izlučuje u crijeva. Odeviksibat
blokira mehanizam koji inače žučne
kiseline ponovno apsorbira iz crijeva nakon što su izvršile svoju
funkciju. Time se omogućuje njihovo
uklanjanje iz tijela putem stolice.
Bylvay se koristi za liječenje progresivne obiteljske intrahepatične
kolestaze (PFIC) u bolesnika u dobi
od 6 mjeseci ili starijih. PFIC je bolest jetre uzrokovana
nakupljanjem žučnih kiselina (kolestaza), koja
se pogoršava tijekom vremena i često je popraćena teškim
svrbežom.
2.
ŠTO MORATE ZN
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Od zdravstvenih radnika traži se da prijave svaku sumnju
na nuspojavu za ovaj lijek. Za
postupak prijavljivanja nuspojava vidjeti dio 4.8.
1.
NAZIV LIJEKA
Bylvay 200 mikrograma tvrde kapsule
Bylvay 400 mikrograma tvrde kapsule
Bylvay 600 mikrograma tvrde kapsule
Bylvay 1200 mikrograma tvrde kapsule
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Bylvay 200 μg tvrde kapsule
Jedna tvrda kapsula sadrži odeviksibat seskvihidrat u količini koja
odgovara 200 mikrograma
odeviksibata.
_ _
_ _
Bylvay 400 μg tvrde kapsule
Jedna tvrda kapsula sadrži odeviksibat seskvihidrat u količini koja
odgovara 400 mikrograma
odeviksibata.
_ _
_ _
Bylvay 600 μg tvrde kapsule
Jedna tvrda kapsula sadrži odeviksibat seskvihidrat u količini koja
odgovara 600 mikrograma
odeviksibata.
_ _
_ _
Bylvay 1200 μg tvrde kapsule
Jedna tvrda kapsula sadrži odeviksibat seskvihidrat u količini koja
odgovara 1200 mikrograma
odeviksibata.
_ _
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Tvrda kapsula
Bylvay 200 μg tvrde kapsule
Kapsula veličine 0 (21,7 mm × 7,64 mm) s neprozirnom kapicom boje
bjelokosti i bijelim neprozirnim
tijelom; oznaka „A200” otisnuta je u crnoj boji.
Bylvay 400 μg tvrde kapsule
Kapsula veličine 3 (15,9 mm × 5,82 mm) s neprozirnom kapicom
narančaste boje i bijelim
neprozirnim tijelom; oznaka „A400” otisnuta je u crnoj boji.
Bylvay 600 μg tvrde kapsule
Kapsula veličine 0 (21,7 mm × 7,64 mm) s neprozirnom kapicom i
tijelom boje bjelokosti; oznaka
„A600” otisnuta je u crnoj boji.
Bylvay 1200 μg tvrde kapsule
3
Kapsula veličine 3 (15,9 mm × 5,82 mm) s neprozirnom kapicom i
tijelom narančaste boje; oznaka
„A1200” otisnuta je u crnoj boji.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Lijek Bylvay indiciran je za liječenje progresivne obiteljske
intrahepatične kolestaze (engl.
_progressive familial intrahepatic cholestasis_
(PF
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-02-2024
Public Assessment Report Public Assessment Report Bulgarian 28-07-2021
Patient Information leaflet Patient Information leaflet Spanish 22-02-2024
Public Assessment Report Public Assessment Report Spanish 28-07-2021
Patient Information leaflet Patient Information leaflet Czech 22-02-2024
Public Assessment Report Public Assessment Report Czech 28-07-2021
Patient Information leaflet Patient Information leaflet Danish 22-02-2024
Public Assessment Report Public Assessment Report Danish 28-07-2021
Patient Information leaflet Patient Information leaflet German 22-02-2024
Public Assessment Report Public Assessment Report German 28-07-2021
Patient Information leaflet Patient Information leaflet Estonian 22-02-2024
Public Assessment Report Public Assessment Report Estonian 28-07-2021
Patient Information leaflet Patient Information leaflet Greek 22-02-2024
Public Assessment Report Public Assessment Report Greek 28-07-2021
Patient Information leaflet Patient Information leaflet English 22-02-2024
Public Assessment Report Public Assessment Report English 28-07-2021
Patient Information leaflet Patient Information leaflet French 22-02-2024
Public Assessment Report Public Assessment Report French 28-07-2021
Patient Information leaflet Patient Information leaflet Italian 22-02-2024
Public Assessment Report Public Assessment Report Italian 28-07-2021
Patient Information leaflet Patient Information leaflet Latvian 22-02-2024
Public Assessment Report Public Assessment Report Latvian 28-07-2021
Patient Information leaflet Patient Information leaflet Lithuanian 22-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-02-2024
Public Assessment Report Public Assessment Report Lithuanian 28-07-2021
Patient Information leaflet Patient Information leaflet Hungarian 22-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 22-02-2024
Public Assessment Report Public Assessment Report Hungarian 28-07-2021
Patient Information leaflet Patient Information leaflet Maltese 22-02-2024
Public Assessment Report Public Assessment Report Maltese 28-07-2021
Patient Information leaflet Patient Information leaflet Dutch 22-02-2024
Public Assessment Report Public Assessment Report Dutch 28-07-2021
Patient Information leaflet Patient Information leaflet Polish 22-02-2024
Public Assessment Report Public Assessment Report Polish 28-07-2021
Patient Information leaflet Patient Information leaflet Portuguese 22-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 22-02-2024
Public Assessment Report Public Assessment Report Portuguese 28-07-2021
Patient Information leaflet Patient Information leaflet Romanian 22-02-2024
Public Assessment Report Public Assessment Report Romanian 28-07-2021
Patient Information leaflet Patient Information leaflet Slovak 22-02-2024
Public Assessment Report Public Assessment Report Slovak 28-07-2021
Patient Information leaflet Patient Information leaflet Slovenian 22-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 22-02-2024
Public Assessment Report Public Assessment Report Slovenian 28-07-2021
Patient Information leaflet Patient Information leaflet Finnish 22-02-2024
Public Assessment Report Public Assessment Report Finnish 28-07-2021
Patient Information leaflet Patient Information leaflet Swedish 22-02-2024
Public Assessment Report Public Assessment Report Swedish 28-07-2021
Patient Information leaflet Patient Information leaflet Norwegian 22-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 22-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 22-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 22-02-2024

Search alerts related to this product

View documents history